

## Quick reference guide

# Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

## 1 Guidance

- 1.1 Cinacalcet is not recommended for the routine treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy.
- 1.2 Cinacalcet is recommended for the treatment of refractory secondary hyperparathyroidism in patients with end-stage renal disease (including those with calciphylaxis) only in those:
- who have 'very uncontrolled' plasma levels of intact parathyroid hormone (defined as greater than 85 pmol/litre [800 pg/ml]) that are refractory to standard therapy, and a normal or high adjusted serum calcium level, and
  - in whom surgical parathyroidectomy is contraindicated, in that the risks of surgery are considered to outweigh the benefits.
- 1.3 Response to treatment should be monitored regularly and treatment should be continued only if a reduction in the plasma levels of intact parathyroid hormone of 30% or more is seen within 4 months of treatment, including dose escalation as appropriate.

## 2 Implementation

NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website ([www.nice.org.uk/TA117](http://www.nice.org.uk/TA117)).

- A costing statement explaining the resource impact of this guidance.
- Audit criteria to monitor local practice.

## NICE technology appraisal guidance 117

### This guidance is written in the following context

This guidance represents the view of the Institute, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

## Further information

### Quick reference guide

This has been distributed to healthcare professionals working in the NHS in England and Wales (see [www.nice.org.uk/TA117distributionlist](http://www.nice.org.uk/TA117distributionlist)). It is available from [www.nice.org.uk/TA117quickrefguide](http://www.nice.org.uk/TA117quickrefguide)

For printed copies, phone the NHS Response Line on 0870 1555 455 (quote reference number N1184).

### Full guidance

This contains the following sections:

- 1 Guidance
- 2 Clinical need and practice
- 3 The technology
- 4 Evidence and interpretation
- 5 Implementation
- 6 Recommendations for further research
- 7 Related NICE guidance
- 8 Review of guidance.

The full guidance also gives details of the Appraisal Committee and the sources of evidence considered. It is available from [www.nice.org.uk/TA117guidance](http://www.nice.org.uk/TA117guidance)

### 'Understanding NICE guidance'

Information for patients with secondary hyperparathyroidism associated with end-stage renal disease and their carers is available from [www.nice.org.uk/TA117publicinfo](http://www.nice.org.uk/TA117publicinfo)

For printed copies, phone the NHS Response Line on 0870 1555 455 (quote reference number N1185).

### Related NICE guidance

- Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure. NICE technology appraisal guidance 48 (2002). Available from: [www.nice.org.uk/TA048](http://www.nice.org.uk/TA048)
- NICE is developing the following guidance (details available from [www.nice.org.uk](http://www.nice.org.uk)).
- Chronic kidney disease: early identification and management of adults with chronic kidney disease in primary and secondary care. NICE clinical guideline (publication expected September 2008).

Published by the National Institute for Health and Clinical Excellence, January 2007; ISBN 1-84629-346-4

© National Institute for Health and Clinical Excellence, January 2007. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of the Institute.